Spherix Global Insights’ analysis of over 2,300 patient charts reveals a global shift in IgA nephropathy (IgAN) treatment, driven by increased SGLT2 inhibitor use and the emergence of targeted therapies like Tarpeyo, Filspari, Fabhalta, and Venrafia. Nephrologists are now incorporating SGLT2 inhibitors earlier in treatment, often alongside RAASi, as foundational care for non-dialysis IgAN patients. This shift also reflects a move towards targeted therapies focused on underlying disease mechanisms.
This evolving treatment landscape represents a significant advancement for IgAN patients who previously had limited treatment options beyond supportive care. The availability of targeted therapies, coupled with the broader use of SGLT2 inhibitors, offers a more nuanced approach to managing IgAN and potentially achieving better patient outcomes. Furthermore, the observed regional variations in treatment approaches, such as tonsillectomy in Japan versus a preference for targeted therapies in the US and China, highlight the need for tailored treatment strategies based on local practices and product availability.
SGLT2 inhibitors are becoming widely adopted as foundational therapy across all markets studied. Tarpeyo and Filspari are gaining traction in the US, with increasing use in earlier lines of therapy. In Europe, Kinpeygo (Tarpeyo) and Filspari are experiencing growth, particularly in Germany and the UK. Nefecon (budesonide) has seen rapid uptake in China. Novartis’ Fabhalta is entering the market for later-line treatment, and Vanrafia is poised to further expand treatment options. Despite these advances, a significant number of patients remain above the target proteinuria level of 0.5g/day, underscoring the need for additional, more effective therapies. Physicians prioritize clinical data demonstrating both proteinuria reduction and eGFR preservation when evaluating new treatments, while safety remains a key consideration.
The introduction of multiple new therapies targeting different disease mechanisms signals a paradigm shift in IgAN management. As clinical experience with these agents grows and further research emerges, treatment guidelines are likely to evolve, further refining the approach to IgAN. The focus on targeted therapies, combined with continued research into novel mechanisms, offers hope for improved outcomes and a better quality of life for individuals living with IgAN.
Jon Napitupulu is Director of Media Relations at The Clinical Trial Vanguard. Jon, a computer data scientist, focuses on the latest clinical trial industry news and trends.
